napththalen-1-yl)ureas, and 1b, a class of indole-pyrimidinyl compounds which were patented respectively, we designed, de novo synthesized, and evaluated two kinds of novel series of lactone benzoyl hydrazine derivatives and 2-nitro-1-phenyl-1H-indole derivatives in an effort to develop pharmacologically tractable agents to alleviate the progression of AD. Fourteen of the seventeen synthesized compounds
抑制p38丝裂原激活的蛋白激酶(
MAPKs)可以显着调节与阿尔茨海默氏病(AD)相关的神经炎症状况。受到天然NF-kappaB和p38alpha
MAPK
抑制剂5,6-脱氢卡哇因和p38alpha
MAPK
抑制剂1a药效的启发,1-
吡唑基-3-(4-(((2-
苯胺基
嘧啶丁-4-基)氧基)
萘并-1-基)
尿素和分别获得专利的一类
吲哚-
嘧啶化合物1b,我们设计,从头合成并评估了两种新型的内酯苯甲酰基
肼衍
生物和2-硝基-
1-苯基-1H-吲哚衍
生物努力开发可治疗药物的药物以减轻AD的病情。十七种合成化合物中的十四种对脂
多糖(LPS)诱导的小胶质细胞活化诱导的
一氧化氮(NO)产生显着抑制作用,其IC50低于对照5,6-脱氢卡哇因。值得注意的是,IC27值为1.6μm的化合物27,6-甲氧基-2-硝基-1-(1H-1,2,2,3-三唑-1-基)-1H-
吲哚可以显着抑制p38alpha
MAPK和NO的释放。